Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 68001-546

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 68001-546). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pemetrexed For Injection 1000mg Label (Image 01)

Pemetrexed For Injection 1000mg Label (Image 01)
Label for Pemetrexed injection, USP, 1000 mg per vial, a lyophilized powder for intravenous use. The label includes storage instructions (20°C to 25°C), a caution note for cytotoxicity, and manufacturer information listing Gland Pharma Limited, India, for BluePoint Laboratories. It specifies single-dose vial usage and contains barcode and lot/expiration fields.*
FDA Label Image

Pemetrexed For Injection 1000mg Carton (Image 02)

Pemetrexed For Injection 1000mg Carton (Image 02)
Packaging label for Pemetrexed for Injection, USP 1000 mg/vial, a cytotoxic agent for intravenous use. The label, from BluePoint Laboratories, includes dosing and storage instructions, reconstitution guidance, and manufacturer details for a single-dose vial. The NDC number shown is 68001-546-41. The label features branding 'OncoPoint' and cautions for intravenous administration.*
FDA Label Image

Structure (Image 03)

Structure (Image 03)
Chemical structure of Pemetrexed disodium shown as a 2D molecular diagram indicating its chemical bonds and functional groups, including the disodium salt and hydration state 2.5 H2O.*
FDA Label Image

Figure 1 (Image 04)

Figure 1 (Image 04)
A Kaplan-Meier survival curve chart depicting overall survival percentage over time in months for two treatment arms labeled P+P+C and P+C. The chart shows a higher survival percentage for P+P+C compared to P+C over 42 months, with a corresponding table below indicating the number of patients at risk at multiple time points.*
FDA Label Image

Figure 2 (Image 05)

Figure 2 (Image 05)
A survival probability Kaplan-Meier curve comparing Pemetrexed plus Cisplatin versus Gemcitabine plus Cisplatin over 30 months. The X-axis represents survival time in months, and the Y-axis shows survival probability. A table below the graph lists the number of patients at risk at various time points for each treatment group.*
FDA Label Image

Figure 3 (Image 06)

Figure 3 (Image 06)
A survival probability chart comparing Pemetrexed + Cisplatin (PC) versus Gemcitabine + Cisplatin (GC) over a 30-month survival time in months. The graph includes a table below showing the number of patients at risk at various intervals for both treatment groups.*
FDA Label Image

Figure 4 (Image 07)

Figure 4 (Image 07)
A Kaplan-Meier survival curve chart showing survival probability over time in months, comparing two treatment groups: Pemetrexed plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC). The chart includes a table listing the number of patients at risk at various time points up to 30 months for each group.*
FDA Label Image

Figure 5 (Image 08)

Figure 5 (Image 08)
A survival probability line graph comparing Pemetrexed versus placebo over survival time in months. The y-axis shows survival probability from 0 to 1, and the x-axis shows survival time from 0 to 42 months. Two lines represent patients treated with Pemetrexed and placebo, with numbers of patients at risk listed below at various months.*
FDA Label Image

Figure 6 (Image 09)

Figure 6 (Image 09)
A survival analysis graph showing survival probability over time in months comparing Pemetrexed and Placebo groups. The Y-axis represents survival probability from 0 to 1, and the X-axis represents survival time in months up to 42. The chart includes a table below showing numbers of patients at risk for each group at various time points.*
FDA Label Image

Figure 7 (Image 10)

Figure 7 (Image 10)
A survival curve graph showing survival probability over time in months, comparing Pemetrexed and Placebo groups. The x-axis represents survival time from 0 to 42 months, and the y-axis shows survival probability from 0 to 1. Below the graph, a table details the number of patients at risk in each group at various time points.*
FDA Label Image

Figure 8 (Image 11)

Figure 8 (Image 11)
A Kaplan-Meier survival curve plot comparing survival probability over time (months) between Pemetrexed and placebo groups. The graph shows survival time on the x-axis and survival probability on the y-axis. A table below the graph lists the number of patients at risk at various time points for both groups.*
FDA Label Image

Figure 9 (Image 12)

Figure 9 (Image 12)
A Kaplan-Meier survival curve comparing survival probability over time (months) for patients treated with Pemetrexed plus Cisplatin versus Cisplatin alone. The graph includes a table listing the number of patients at risk at various time points for each treatment group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.